Gemma joined Anglia Ruskin University in 2021 as a lecturer in Biomedical Science. Gemma’s research focuses on insulin resistance and investigating the therapeutic potential of antibodies to treat severe insulin resistance arising from mutations of the insulin receptor. Her wider interest encompasses understanding the (patho)physiological role of hybrid insulin/IGF receptors in insulin resistance and resultant co-morbidities.
Gemma completed her PhD at the University of Adelaide, Australia (including a sabbatical at the Weatherall Institute of Molecular Medicine, University of Oxford) where she investigated the interplay between insulin and IGF receptors and how they signal outcomes relevant to cancer biology. She was a Postdoctoral Fellow at the Commonwealth Scientific Industrial Research Organisation (CSIRO) in South Australia where she worked on a varied and commercially orientated body of work relating to improving early detection and diagnosis of colorectal cancer. Gemma then moved to the UK to undertake a second postdoctoral position at the University of Cambridge, Wellcome Trust – MRC Institute of Metabolic Science (where she maintains Visiting Scientist status) during which she expanded her understanding of the insulin/IGF system from its role in cancer biology to its role in metabolism.
Fellow: Diabetes UK Innovators in Diabetes programme (2018 – 2021)
Fellow: Emerging Research Leaders Development Programme, University of Cambridge (2018)
Postdoctoral By-fellow: Churchill College, University of Cambridge (2017 – 2019)
Brierley, G.V. and Semple, R. K. 2021. Insulin at 100 years – is rebalancing its action key to fighting obesity-related disease? Dis Model Mech. 14(11):dmm049340
Gage, M.C., Harrington, D., Brierley, G.V., et al. 2021. Challenges and solutions for diabetes early career researchers in the COVID-19 recovery: Perspectives of the Diabetes UK Innovators in Diabetes. Diabet Med. Sep 25:e14698
Hammerle, C.M., Sandovici, I., Brierley, G.V., et al. 2020. Mesenchyme-derived IGF2 is a major paracrine regulator of pancreatic growth and function. PLoS Genetics. 16(10):e1009069
Brierley, G.V., et al., 2020. Anti-Insulin receptor antibodies improve hyperglycemia in a mouse model of human insulin receptoropathy. Diabetes. 69(11): 2481 – 2489
Brierley, G.V., Siddle, K., and Semple, R.K., 2018. Evaluation of anti-insulin receptor antibodies as potential novel therapies for human insulin receptoropathy using cell culture models. Diabetologia. 61(7): 1662 - 1675